Medvi is a U.S.-based telehealth platform that provides online access to prescription erectile dysfunction treatment through a remote medical review process. The brand emphasizes privacy and simplified access, allowing users to complete an online intake instead of visiting a doctor’s office in person.
For erectile dysfunction, Medvi promotes its proprietary QUAD® formulation, which combines multiple PDE5 inhibitors along with apomorphine into a single compounded prescription. If a user is approved following medical review, the medication is shipped directly to their address.
According to the American Urological Association (AUA), oral PDE5 inhibitors are considered first-line therapy for most men with ED who do not have contraindications. Each component in Medvi’s formulation has individual clinical evidence supporting its use. However, the exact combined QUAD® formulation has not been studied in large-scale randomized trials.
The service emphasizes discreet delivery, transparent per-dose pricing, and remote clinician oversight, while requiring users to carefully review medical eligibility, compounded-drug considerations, and billing terms before purchase.
Medvi’s process begins with an online health questionnaire. A licensed medical professional reviews the information to determine eligibility. If approved, the prescription is sent to a pharmacy and shipped directly to the user.
Telehealth platforms like Medvi can expand access to treatment and improve convenience. However, erectile dysfunction may also be associated with underlying cardiovascular or metabolic conditions, and in some cases, in-person evaluation and broader cardiovascular risk assessment may be clinically appropriate.
Users must disclose all medications and relevant health conditions during intake to ensure safe prescribing.
Medvi lists pricing on a per-dose basis, commonly referenced at approximately $12 per dose, with package options such as 10 or 20 doses. Some promotional pages may display lower introductory pricing, so the final cost should always be confirmed at checkout.
Medvi’s policies indicate that certain programs may be auto-renewing, and refund eligibility may be limited. Users should review subscription terms, cancellation policies, and billing disclosures carefully before purchase.
PDE5 inhibitors work by enhancing nitric oxide–mediated vasodilation. These medications are contraindicated in individuals using nitrates or soluble guanylate cyclase stimulators due to the risk of significant hypotension. Caution is also advised in patients with unstable cardiovascular disease, recent heart attack or stroke, uncontrolled hypertension, or advanced heart failure.
Because Medvi’s QUAD® formulation includes multiple PDE5 inhibitors, additive blood-pressure–lowering effects may theoretically increase the likelihood of dose-related adverse effects such as headache, flushing, dizziness, nasal congestion, visual changes, or hypotension. Patients should disclose all medications and cardiovascular history during screening.
Erectile dysfunction can also serve as an early marker of systemic vascular disease. Men with new, progressive, or sudden-onset ED — particularly if associated with exertional chest discomfort or reduced exercise tolerance — should consider seeking in-person medical evaluation.
Medvi’s QUAD® formulation is a compounded medication. Compounded drugs are not FDA-approved and do not undergo the same premarket evaluation for safety, effectiveness, or manufacturing consistency as FDA-approved medications.
Medvi lists multiple support channels, including:
Email: help@medvi.org
Phone: (323) 690-1564
Physical Address: 131 Continental Dr. Ste 305, Newark, DE 19713
The company promotes access to medical support and telehealth communication. However, specific response times and staffing hours are not detailed on pricing pages, so users may wish to confirm support availability during enrollment.
Medvi differentiates itself by offering a compounded multi-agent ED formulation rather than a single-drug prescription. For some users, this may represent an alternative approach if single-agent therapy has been insufficient. However, the combined formulation has not been evaluated in large randomized trials and is prescribed at clinician discretion.
Another distinguishing feature is transparent per-dose pricing, allowing users to compare short-term package options rather than committing immediately to long-term membership tiers.
The fully remote intake and fulfillment model also supports privacy and convenience, eliminating the need for in-person clinic visits.
Medvi provides telehealth-based access to prescription erectile dysfunction treatment with per-dose pricing transparency and discreet shipping. Its primary differentiator is the QUAD® compounded multi-agent formulation.
While individual PDE5 inhibitors are supported by strong clinical evidence and guideline recommendations, the specific compounded combination offered by Medvi has not been evaluated in large randomized trials and is not FDA-approved. Users should weigh convenience and pricing structure against regulatory and evidence considerations and ensure appropriate cardiovascular screening when indicated.
This review was compiled using Medvi’s ED product pages and Medvi’s posted policy/consent pages, along with third-party review aggregators for general reputation signals and FDA/NIDDK references for ED and compounded-drug safety context.
Having explored the features and benefits of this product, you might be curious about how it stacks up against its competitors. We encourage you to visit our comprehensive comparison chart for a broader perspective. This chart offers a detailed juxtaposition of this product with other leading brands, highlighting differences in features, pricing, and customer ratings. It’s an invaluable resource for contrasting your options and making an informed decision that best suits your needs. Don’t miss out – take a moment now to view our comparison chart and see how your chosen product compares in the wider market.
AI was used in the creation of this content, along with human validation and proofreading.
Thomas Hatzilabrou, M.D. is a U.S.-based Internal Medicine physician and top-ranked ResearchHub peer reviewer with extensive experience across medicine, biology, and related sciences. He has designed and led randomized controlled trials, authored numerous cohort, cross-sectional, and case studies, and published multiple peer-reviewed articles.